Oral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patients

Hormone and Metabolic Research

Volumn 42, Issue 1, 2010, Pages 8-13

  Derosa, G ^a   Dangelo, A ^a   Salvadeo, S A T ^a   Ferrari, I ^a   Fogari, E ^a   Gravina, A ^a   Mereu, R ^a   Palumbo, I ^a   Maffioli, P ^a   Randazzo, S ^a   Cicero, A F G ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cardiovascular risk; Soluble adhesion molecules; Type 2 diabetes mellitus; Vessels dysfunction

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; VASCULITIS;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM; ENDOTHELIUM, VASCULAR; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 73949129021     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0029-1237728     Document Type: Article

References (39)

1. Stirban AO, Tschoepe D. Cardiovascular complications in diabetes: targets and interventions. Diabetes Care 2008 31 (Suppl 2) S215-S221
2. Bartnik M, Norhammar A, Rydén L. Hyperglycaemia and cardiovascular disease. J Intern Med 2007 262 145-156
3. Milicevic Z, Raz I, Beattie SD, Campaigne BN, Sarwat S, Gromniak E, Kowalska I, Galic E, Tan M, Hanefeld M. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care 2008 31 (Suppl 2) S155-S160
4. Asadollahi K, Beeching N, Gill G. Hyperglycaemia and mortality. J R Soc Med 2007 100 503-507
5. Bell DS, OKeefe JH, Jellinger P. Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events? Endocr Pract 2008 14 112-124
6. Petersen JL, McGuire DK. Impaired glucose tolerance and impaired fasting glucose a review of diagnosis, clinical implications and management. Diab Vasc Dis Res 2005 2 9-15
7. American Diabetes Association. Screening for diabetes (Position Statement). Diabetes Care 2001 24 S21-S24
8. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of WHO Consultation on Obesity Geneva: WHO June 1997
9. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diab Med 1999 16 716-730
10. Song M, Kellum JA. Interleukin-6. Crit Care Med 2005 33 S463-465
11. Zhang M, Tracey K. The Cytokine Handbook. 3rd ed San Diego: Academic Press 1988
12. Rifai N, Tracy RP, Ridker PM. Clinical Efficacy of an Automated High-Sensitivity C-Reactive Protein Assay. Clin Chem 1999 45 2136-2141
13. Witkowska AM, Borawska MH. Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. Eur Cytokine Netw 2004 15 91-98
14. Peter K, Weirich U, Nordt TK, Ruef J, Bode C. Soluble vascular cell adhesion molecule-1 (VCAM-1) as potential marker of atherosclerosis. Thromb Haemost 1999 82 38-43
15. Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta 2006 368 33-47
16. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care 2007 30 S4-S41
17. Winer BJ. Statistical Principles in Experimental Design. 2nd ed New York: McGraw-Hill 1971
18. Matthews JNS, Altman DG, Campbell MJ, Royton P. Analysis of serial measurements in medical research. BMJ 1990 300 230-235
19. Tanabe N, Saito K, Yamada Y, Takasawa T, Seki N, Suzuki H. Risk assessment by post-challenge plasma glucose, insulin response ratio, and other indices of insulin resistance and/or secretion for predicting the development of type 2 diabetes. Intern Med 2009 48 401-409
20. Ferri C, Desideri G, Baldoncini R, Bellini C, De Angelis C, Mazzocchi C, Santucci A. Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities. Diabetes 1998 47 660-667
21. Matsumoto K, Miyake S, Yano M, Ueki Y, Tominaga Y. High serum concentrations of soluble E-selectin in patients with impaired glucose tolerance with hyperinsulinemia. Atherosclerosis 2000 152 415-420
22. Blüher M, Unger R, Rassoul F, Richter V, Paschke R. Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes. Diabetologia 2002 45 210-216
23. Morohoshi M, Fujisawa K, Uchimura I, Numano F. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes 1996 45 954-959
24. Ruotsalainen E, Vauhkonen I, Salmenniemi U, Pihlajamäki J, Punnonen K, Kainulainen S, Jalkanen S, Salmi M, Laakso M. Markers of endothelial dysfunction and low-grade inflammation are associated in the offspring of type 2 diabetic subjects. Atherosclerosis 2008 197 271-277
25. Kowalska I, Straczkowski M, Szelachowska M, Kinalska I, Prokop J, Bachórzewska-Gajewska H, Stepien A. Circulating E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in men with coronary artery disease assessed by angiography and disturbances of carbohydrate metabolism. Metabolism 2002 51 733-736
26. Morohoshi M, Fujisawa K, Uchimura I, Numano F. The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes. Ann N Y Acad Sci 1995 748 562-570
27. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 2000 85 2970-2973
28. Ceriello A, Assaloni R, Da Ros R, Maier A, Piconi L, Quagliaro L, Esposito K, Giugliano D. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005 111 2518-2524
29. Aljada A, Friedman J, Ghanim H, Mohanty P, Hofmeyer D, Chaudhuri A, Dandona P. Glucose ingestion induces an increase in intranuclear nuclear factor kappaB, a fall in cellular inhibitor kappaB, and an increase in tumor necrosis factor alpha messenger RNA by mononuclear cells in healthy human subjects. Metabolism 2006 55 1177-1185
30. Dhindsa S, Tripathy D, Mohanty P, Ghanim H, Syed T, Aljada A, Dandona P. Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear nuclear factor-kappaB in mononuclear cells. Metabolism 2004 53 330-334
31. Ceriello A, Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, Esposito K, Giugliano D. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004 53 701-710
32. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002 106 2067-2072
33. Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari AM, Paolisso G, Marfella R, Giugliano D. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 2002 39 1145-1150
34. Kempf K, Rose B, Herder C, Kleophas U, Martin S, Kolb U. Inflammation in Metabolic Syndrome and Type 2 Diabetes. Impact of Dietary Glucose. Ann N Y Acad Sci 2006 1084 30-48
35. Derosa G, DAngelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF. Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. Intern Med 2007 46 1837-1846
36. Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004 26 744-754
37. LeRoith D. Treatment of diabetes: a clinical update on insulin trials. Clin Cornerstone 2007 8 2129
38. Derosa G, Fogari E, Cicero AF, DAngelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Gravina A, Ferrari I, Fogari R. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res 2007 30 387394
39. Bogdanski P, Pupek-Musialik D, Dytfeld J, Jagodzinski PP, Jablecka A, Kujawa A, Musialik K. Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus. Int J Clin Pharmacol Ther 2007 45 563-567